Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
| Autor: | Thomas Peyret, J.F. Marier, Claudia Jomphe, Yi Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Short Bowel Syndrome medicine.medical_specialty Parenteral Nutrition Adolescent Population Cmax Renal function RM1-950 Teduglutide Gastroenterology General Biochemistry Genetics and Molecular Biology Article chemistry.chemical_compound Young Adult Pharmacokinetics Gastrointestinal Agents Japan Internal medicine Medicine Humans Dosing General Pharmacology Toxicology and Pharmaceutics education Child Aged Volume of distribution education.field_of_study business.industry General Neuroscience Research Infant General Medicine Articles Middle Aged Short bowel syndrome medicine.disease chemistry Child Preschool Therapeutics. Pharmacology Public aspects of medicine RA1-1270 business Peptides |
| Zdroj: | Clinical and Translational Science, Vol 14, Iss 6, Pp 2497-2509 (2021) Clinical and Translational Science |
| ISSN: | 1752-8054 1752-8062 |
| Popis: | Teduglutide is a recombinant analog of human glucagon‐like peptide‐2 that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. Teduglutide is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support (PS). Population pharmacokinetic (PK) and exposure‐response analyses were performed to support teduglutide dosing in patients with SBS. The analysis included 219 patients with SBS (aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|